Robeco Institutional Asset Management B.V. Has $246.07 Million Position in Pfizer Inc. $PFE

Robeco Institutional Asset Management B.V. raised its holdings in Pfizer Inc. (NYSE:PFE) by 36.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 10,151,483 shares of the biopharmaceutical company’s stock after buying an additional 2,720,184 shares during the period. Robeco Institutional Asset Management B.V. owned 0.18% of Pfizer worth $246,072,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer in the 1st quarter valued at about $27,000. North Capital Inc. bought a new position in shares of Pfizer in the 1st quarter valued at about $28,000. Bayforest Capital Ltd bought a new position in shares of Pfizer in the 1st quarter valued at about $28,000. Horizon Financial Services LLC bought a new position in shares of Pfizer in the 1st quarter valued at about $35,000. Finally, WPG Advisers LLC bought a new stake in shares of Pfizer during the 1st quarter worth about $35,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of Pfizer stock opened at $27.21 on Thursday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The company has a 50-day simple moving average of $24.59 and a two-hundred day simple moving average of $24.14. The stock has a market capitalization of $154.68 billion, a price-to-earnings ratio of 14.47, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter in the previous year, the company earned $0.60 EPS. The business’s revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently commented on PFE. UBS Group reaffirmed a “neutral” rating and set a $28.00 target price on shares of Pfizer in a report on Wednesday. Morgan Stanley lifted their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. Citigroup lifted their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Bank of America lifted their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Finally, Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus target price of $28.29.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.